Your browser is no longer supported. Please, upgrade your browser.
Settings
LXRX Lexicon Pharmaceuticals, Inc. daily Stock Chart
LXRX [NASD]
Lexicon Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.33 Insider Own0.10% Shs Outstand106.90M Perf Week-0.45%
Market Cap1.19B Forward P/E- EPS next Y-0.96 Insider Trans40.84% Shs Float105.30M Perf Month-12.88%
Income-138.40M PEG- EPS next Q-0.36 Inst Own- Short Float13.98% Perf Quarter-34.66%
Sales81.10M P/S14.71 EPS this Y-8.10% Inst Trans-0.04% Short Ratio21.07 Perf Half Y-26.14%
Book/sh1.01 P/B11.05 EPS next Y34.70% ROA-31.60% Target Price26.40 Perf Year-31.07%
Cash/sh2.16 P/C5.16 EPS next 5Y- ROE-94.90% 52W Range10.96 - 18.00 Perf YTD-19.31%
Dividend- P/FCF- EPS past 5Y10.60% ROI-53.00% 52W High-38.00% Beta0.15
Dividend %- Quick Ratio1.90 Sales past 5Y114.20% Gross Margin99.10% 52W Low1.82% ATR0.44
Employees168 Current Ratio1.90 Sales Q/Q-39.80% Oper. Margin- RSI (14)33.35 Volatility2.50% 3.10%
OptionableYes Debt/Eq0.95 EPS Q/Q9.30% Profit Margin- Rel Volume0.83 Prev Close11.34
ShortableYes LT Debt/Eq0.80 EarningsOct 31 BMO Payout- Avg Volume698.89K Price11.16
Recom2.00 SMA20-5.55% SMA50-15.23% SMA200-24.57% Volume576,704 Change-1.59%
Mar-01-17Reiterated Wedbush Outperform $33 → $38
Mar-01-17Reiterated H.C. Wainwright Buy $26 → $27
Oct-07-16Initiated H.C. Wainwright Buy $26
Aug-05-16Reiterated Wedbush Outperform $30 → $31
Aug-02-16Initiated Citigroup Buy $21
Mar-02-16Reiterated Wedbush Outperform $26 → $28
Nov-09-15Reiterated Wedbush Outperform $19 → $26
Sep-28-15Upgrade Gabelli & Co Sell → Hold
Sep-18-15Downgrade Gabelli & Co Hold → Sell
Aug-10-15Downgrade JP Morgan Overweight → Neutral
Aug-19-14Downgrade Gabelli & Co Buy → Hold
Jun-26-12Reiterated Stifel Nicolaus Buy $3 → $4
Apr-26-11Initiated Wedbush Outperform $3
Oct-29-08Downgrade Piper Jaffray Neutral → Sell
Mar-07-08Downgrade Piper Jaffray Buy → Neutral
Oct-31-07Downgrade RBC Capital Mkts Outperform → Sector Perform $6 → $5
Aug-07-07Reiterated Punk, Ziegel & Co Buy $24 → $7
May-15-07Initiated Banc of America Sec Buy $6
Oct-17-17 08:02AM  See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc. Markit
Oct-16-17 09:56AM  ETFs with exposure to Lexicon Pharmaceuticals, Inc. : October 16, 2017 Capital Cube
08:01AM  See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc. Markit
Oct-08-17 09:23AM  News Flash: The FDA Just Approved a Breakthrough Diabetes Device Motley Fool
Oct-05-17 11:10AM  ETFs with exposure to Lexicon Pharmaceuticals, Inc. : October 5, 2017 Capital Cube
Oct-04-17 09:10AM  Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017 Capital Cube
08:02AM  See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc. Markit
Oct-03-17 08:03AM  See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc. Markit
Oct-02-17 08:03AM  See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc. Markit
Sep-27-17 07:00AM  Lexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211 PR Newswire
Sep-19-17 12:33PM  European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy PR Newswire
Sep-18-17 07:00AM  Lexicon Pharmaceuticals To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-14-17 05:16PM  Slashing Fair Value Estimate on Lexicon Pharmaceuticals Morningstar -9.96%
12:32PM  Why Lexicon Pharmaceuticals Is Down 11% Today Motley Fool
Sep-13-17 04:31AM  New England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes PR Newswire -6.65%
Sep-11-17 08:01AM  See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc. Markit
Sep-08-17 07:00AM  Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 inTandem1 And inTandem2 Studies Of Sotagliflozin PR Newswire
Sep-07-17 07:00AM  Lexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Global Healthcare Conference PR Newswire
07:00AM  Lexicon Pharmaceuticals Announces Four Data Presentations At The European Society Of Medical Oncology 2017 Congress PR Newswire
Sep-05-17 07:00AM  Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting PR Newswire
Sep-01-17 12:08PM  5 of the Most Hated Biotech Stocks on the Market: Are They Buys? Motley Fool
Aug-17-17 08:02AM  See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc. Markit
Aug-15-17 07:00AM  Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin PR Newswire
Aug-12-17 02:56AM  Edited Transcript of LXRX earnings conference call or presentation 1-Aug-17 12:00pm GMT Thomson Reuters StreetEvents
Aug-03-17 07:00AM  Lexicon Pharmaceuticals To Present At 2017 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-02-17 09:16AM  Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : August 2, 2017 Capital Cube
Aug-01-17 09:32PM  Lexicon reports 2Q loss Associated Press
06:50PM  Lexicon Pharmaceuticals, Inc. Value Analysis (NASDAQ:LXRX) : August 1, 2017 Capital Cube
07:00AM  Lexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business Update PR Newswire
Jul-31-17 06:01PM  Lexicon Pharmaceuticals Announces Opt-In Decision For U.S. Co-Promotion Of Sotagliflozin With Sanofi In Type 1 Diabetes PR Newswire
Jul-25-17 10:08AM  3 Stocks That Could Be Life-Changers Motley Fool
Jul-24-17 09:00AM  Lexicon Pharmaceuticals To Host Second Quarter 2017 Financial Results Conference Call And Webcast On August 1, 2017 PR Newswire
Jul-21-17 07:27AM  Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl) PR Newswire
Jul-19-17 09:10AM  Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : July 19, 2017 Capital Cube
Jun-19-17 07:00AM  NCCN Guidelines For Neuroendocrine Tumors Include XERMELO In Combination With Somatostatin Analog Therapy As A Recommended Treatment Option For Patients With Carcinoid Syndrome Diarrhea PR Newswire
Jun-18-17 09:07AM  3 Top Healthcare Stocks You Haven't Thought Of Motley Fool
Jun-16-17 07:41AM  3 Top-Performing Biotech Stocks This Week Motley Fool
Jun-14-17 12:11AM  Edited Transcript of LXRX earnings conference call or presentation 2-May-17 10:00pm GMT Thomson Reuters StreetEvents
Jun-12-17 10:15AM  Company News for June 12, 2017 Zacks
08:15AM  Corporate News Blog - Lexicon Pharma's Diabetes Drug Sotagliflozin Shows Positive Top-line Results During Phase-3 Intandem3 Clinical Trials Accesswire
08:00AM  Today's Research Reports on Stocks to Watch: Lexicon Pharmaceuticals and Adamis Pharmaceuticals Accesswire
Jun-10-17 01:01PM  Sotagliflozin Data from Pivotal inTandem1 and inTandem2 Studies in Patients with Type 1 Diabetes Presented at ADA 2017 PR Newswire
Jun-09-17 08:45AM  Lexicon Pharmaceuticals Rises on Late-Stage Diabetes Trial 24/7 Wall St. +6.77%
07:01AM  Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes PR Newswire
Jun-05-17 04:01PM  Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions PR Newswire
08:42AM  Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : June 5, 2017 Capital Cube
May-31-17 01:15PM  Lexicon Pharmaceuticals To Present At Upcoming Investor Conferences PR Newswire
May-23-17 12:56PM  ETFs with exposure to Lexicon Pharmaceuticals, Inc. : May 23, 2017 Capital Cube
May-18-17 08:38AM  Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : May 18, 2017 Capital Cube
May-11-17 05:04PM  ETFs with exposure to Lexicon Pharmaceuticals, Inc. : May 11, 2017 Capital Cube
06:30AM  Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal InTandem1 Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes PR Newswire
May-09-17 11:11AM  Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 Capital Cube
May-05-17 01:16PM  Edited Transcript of LXRX earnings conference call or presentation 2-May-17 10:00pm GMT Thomson Reuters StreetEvents
May-04-17 03:09PM  Lexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference PR Newswire
May-03-17 05:02AM  Lexicon reports 1Q loss Associated Press
May-02-17 04:44PM  Lexicon Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides A Business Update PR Newswire
Apr-28-17 01:34PM  Lexicon Pharmaceuticals To Host First Quarter 2017 Financial Results Conference Call And Webcast On May 2, 2017 PR Newswire
Apr-26-17 04:16PM  Lexicon Pharmaceuticals, Inc. Value Analysis (NASDAQ:LXRX) : April 26, 2017 Capital Cube
Apr-25-17 03:39PM  ETFs with exposure to Lexicon Pharmaceuticals, Inc. : April 25, 2017 Capital Cube
09:01AM  Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : April 25, 2017 Capital Cube
Apr-14-17 08:05AM  Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : April 14, 2017 Capital Cube
Apr-03-17 04:23PM  3 Top Biotech Stocks to Buy in April Motley Fool
04:23PM  3 Top Biotech Stocks to Buy in April at Motley Fool
07:00AM  Lexicon To Present At The 16th Annual Needham Healthcare Conference PR Newswire
Mar-31-17 04:10PM  What Does Big Pharma Want To Buy? 3 Drugmakers On Merger Track Investor's Business Daily
04:10PM  What Does Big Pharma Want To Buy? 3 Drugmakers On Merger Track
Mar-26-17 09:03AM  3 Tremendously Promising Diabetes Drugs Potentially on the Way Motley Fool
09:03AM  3 Tremendously Promising Diabetes Drugs Potentially on the Way at Motley Fool
Mar-20-17 08:20AM  Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : March 20, 2017 Capital Cube
08:20AM  Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : March 20, 2017
Mar-15-17 08:45AM  Surging Earnings Estimates Signal Good News for Lexicon (LXRX) Zacks
Mar-09-17 01:04PM  LEXICON PHARMACEUTICALS, INC. Financials
08:00AM  Lexicon To Present At The Barclays Global Healthcare Conference PR Newswire
Mar-07-17 11:55AM  Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Capital Cube
11:55AM  Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
Mar-06-17 05:38PM  Lexicon To Present At The Cowen And Company 37th Annual Healthcare Conference PR Newswire
09:00AM  LEXICON PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Mar-03-17 02:32PM  Edited Transcript of LXRX earnings conference call or presentation 3-Mar-17 3:00pm GMT +6.77%
09:55AM  Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential
09:41AM  Biotech Premarket Movers: Karyopharm, Lexicon, Prothena
08:58AM  LEXICON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:19AM  Lexicon reports 4Q loss
07:00AM  Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results PR Newswire
Mar-02-17 09:30AM  Biotech's Outlook Strengthens After President Trump's Speech: Today's Reports on Dynavax Technologies and Lexicon Pharmaceuticals Accesswire
Mar-01-17 04:39PM  Lexicon To Report Fourth Quarter And Year End 2016 Financial Results On March 3, 2017 PR Newswire
03:47PM  Heres Whats Next For Lexicon Pharmaceuticals, Inc. (LXRX) And Dynavax Technologies Corporation (DVAX) at Insider Monkey
11:33AM  Lexicon Stock Spikes 8% on Diarrhea Drug Approval at Investopedia
Feb-28-17 05:09PM  UPDATE 1-FDA approves Lexicon Pharma's carcinoid syndrome diarrhea drug Reuters
04:53PM  FDA approves Lexicon Pharma's carcinoid syndrome diarrhea drug Reuters
03:56PM  FDA Approves Lexicon Drug XERMELO (telotristat ethyl) 250 mg As First And Only Oral Treatment For Carcinoid Syndrome Diarrhea In Cancer Patients With Metastatic Neuroendocrine Tumors PR Newswire
Feb-15-17 07:34PM  3 Stocks We're Watching in the First Quarter at Motley Fool
Feb-13-17 04:01PM  Lexicon To Present At The Leerink Partners 6th Annual Global Healthcare Conference PR Newswire -5.05%
Feb-01-17 09:30AM  The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals
Jan-31-17 06:43AM  4 FDA Decisions to Watch Out for in Feb 2017
Jan-26-17 04:28PM  5 Small-Cap Biotech Stocks to Buy in February at Motley Fool
Jan-18-17 09:26AM  5 Biotech Stocks You'll Want to Watch in the 1st Quarter at Motley Fool
Jan-09-17 08:00AM  Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes PR Newswire
Jan-05-17 04:30PM  Lexicon To Present At The 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-30-16 07:45AM  7 Key FDA Decisions and Catalysts Expected in January and February at 24/7 Wall St.
Dec-22-16 08:15AM  Blog Coverage Lexicon Pharma's Tandem2 Phase 3 Clinical Trial of Sotagliflozin Met its Primary Endpoint Accesswire -6.50%
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain. The company has license and collaboration agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COATS LONNELPresident and CEOSep 15Buy12.5430,000376,33732,985Sep 18 06:40 AM
BARKER SAM LDirectorSep 15Buy12.501,00012,50025,623Sep 18 06:36 AM